WO2005051350A3 - Water dispersible tablet - Google Patents

Water dispersible tablet Download PDF

Info

Publication number
WO2005051350A3
WO2005051350A3 PCT/IN2004/000312 IN2004000312W WO2005051350A3 WO 2005051350 A3 WO2005051350 A3 WO 2005051350A3 IN 2004000312 W IN2004000312 W IN 2004000312W WO 2005051350 A3 WO2005051350 A3 WO 2005051350A3
Authority
WO
WIPO (PCT)
Prior art keywords
water dispersible
dispersible tablet
formulation
relates
dispersible formulation
Prior art date
Application number
PCT/IN2004/000312
Other languages
French (fr)
Other versions
WO2005051350B1 (en
WO2005051350A2 (en
Inventor
Vinod Kumar Gupta
Navin Vaya
Pramanick Sougata
Original Assignee
Torrent Pharmaceuticals Ltd
Vinod Kumar Gupta
Navin Vaya
Pramanick Sougata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd, Vinod Kumar Gupta, Navin Vaya, Pramanick Sougata filed Critical Torrent Pharmaceuticals Ltd
Publication of WO2005051350A2 publication Critical patent/WO2005051350A2/en
Publication of WO2005051350A3 publication Critical patent/WO2005051350A3/en
Publication of WO2005051350B1 publication Critical patent/WO2005051350B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to a water dispersible formulation of an active pharmaceutical ingredient or pharmaceutically acceptable slat hereof and one or more adjuvants without the use of swellable clay. More particularly, the invention comprises a dispersible formulation of anti-epileptic drug - lamotrigine. This invention further relates to a process for the preparation of said formulation.
PCT/IN2004/000312 2003-10-28 2004-10-07 Water dispersible tablet WO2005051350A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1128MU2003 2003-10-28
IN1128/MUM/2003 2003-10-28

Publications (3)

Publication Number Publication Date
WO2005051350A2 WO2005051350A2 (en) 2005-06-09
WO2005051350A3 true WO2005051350A3 (en) 2005-08-18
WO2005051350B1 WO2005051350B1 (en) 2005-09-29

Family

ID=34631118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000312 WO2005051350A2 (en) 2003-10-28 2004-10-07 Water dispersible tablet

Country Status (1)

Country Link
WO (1) WO2005051350A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
US20070059360A1 (en) * 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions
GB0517205D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
DE102005048293A1 (en) * 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retard formulation for pralnacasan
CN102379866A (en) * 2006-01-18 2012-03-21 霍夫曼-拉罗奇有限公司 Pharmaceutical composition and process
US20100016322A1 (en) * 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
WO2009063484A2 (en) * 2007-08-03 2009-05-22 Alkem Laboratories Ltd Stable pharmaceutical composition of lamotrigine
KR101041203B1 (en) 2007-09-25 2011-06-13 테바 파마슈티컬 인더스트리즈 리미티드 Stable Imatinib Composition
HU230877B1 (en) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable pharmaceutical combination
HUE033115T2 (en) 2009-05-19 2017-11-28 Celgene Corp Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
EP3407874B1 (en) 2016-01-25 2024-05-22 KRKA, d.d., Novo mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
JP2019530727A (en) 2016-10-11 2019-10-24 オクタ ファーマシューティカルズ Powder for oral suspension containing lamotrigine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181650A1 (en) * 1984-11-13 1986-05-21 Gist-Brocades N.V. Compression-coated dispersible tablets
EP0396335A1 (en) * 1989-04-28 1990-11-07 Beecham Group p.l.c. Pharmaceutical formulation
WO1995005179A1 (en) * 1993-08-18 1995-02-23 The Wellcome Foundation Limited Therapeutic combination containing an anti-varicella zoster virus compound and lamotrigine
US20040043996A1 (en) * 2002-06-07 2004-03-04 Nadkarni Sunil Sadanand Controlled release formulation of lamotrigine
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181650A1 (en) * 1984-11-13 1986-05-21 Gist-Brocades N.V. Compression-coated dispersible tablets
EP0396335A1 (en) * 1989-04-28 1990-11-07 Beecham Group p.l.c. Pharmaceutical formulation
WO1995005179A1 (en) * 1993-08-18 1995-02-23 The Wellcome Foundation Limited Therapeutic combination containing an anti-varicella zoster virus compound and lamotrigine
US20040043996A1 (en) * 2002-06-07 2004-03-04 Nadkarni Sunil Sadanand Controlled release formulation of lamotrigine
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "LAMICTAL DISPERSIBLE LAMOTRIGINE", April 2003 (2003-04-01), XP002297185, Retrieved from the Internet <URL:http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=3954> [retrieved on 20050525] *

Also Published As

Publication number Publication date
WO2005051350B1 (en) 2005-09-29
WO2005051350A2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
NO20043702L (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
AU2001230892A1 (en) Orally administered pharmaceutical formulations of benzimidazole derivatives andthe method of preparing the same
WO2001022791A3 (en) Controlled release compositions comprising nimesulide
DK1498411T3 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
BG108516A (en) Pharmaceutical formulation
WO2005117895A3 (en) Compositions comprising meloxicam
WO2005051350A3 (en) Water dispersible tablet
AU2002354054A1 (en) Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
WO2005007137A8 (en) Tablets containing ambroxol
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
MXPA03008420A (en) Solid orally-dispersible pharmaceutical formulation.
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
ATE286894T1 (en) 2H-1-BENZOPYRAN DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS
WO2003041656A3 (en) Soluble drug extended release system
WO2008004100A9 (en) Therapeutic compounds
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050804

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase